Article

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties

2026-04-24

Abstract excerpt

<title>Abstract</title> Background: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor–pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody–drug conjugates (ADCs) have demonstrated transformative efficacy in multiple malignancies, yet ADCs evaluated in patients with metastatic APMR have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b54a78e6-91b4-50eb-85e9-724a81ad2ca6
DOI: 10.21203/rs.3.rs-9194287/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory PropertiesDOI 10.21203/rs.3.rs-9194287/v1Read

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancerSemantic proximity Read

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapySemantic proximity Read

PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity Read

A multifunctional T-cell engager containing CD80 enhances prostate cancer treatmentSemantic proximity Read

Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer CellsSemantic proximity Read

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.Semantic proximity Read

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read

CD46 targeted 212 Pb alpha particle radioimmunotherapy for prostate cancer treatmentSemantic proximity Read

PROTACs in the Management of Prostate Cancer.Semantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerSemantic proximity Read

In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read